Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, R&D spend, and cash-runway figures in Arcutis Biotherapeutics (ARQT) SEC documents can stretch across hundreds of pages. If you need to know how ZORYVE sales offset development costs or where the next PDE4 program stands, wading through every quarterly update is time-consuming and complex.
Stock Titan solves this problem with AI-powered summaries that turn raw disclosures into plain-English takeaways. Whether you are searching for “Arcutis quarterly earnings report 10-Q filing,” want “Arcutis insider trading Form 4 transactions,” or need an “Arcutis proxy statement executive compensation” breakdown, our engine surfaces the exact paragraph in seconds. Real-time alerts appear the moment an “Arcutis Form 4 insider transactions real-time” notice hits EDGAR, while cross-links let you compare each metric historically for quick “Arcutis earnings report filing analysis.”
Dive deeper without the jargon: jump straight to liquidity tables in the “Arcutis annual report 10-K simplified,” scan risk-factor changes, or review pivotal Phase 3 data inside an “Arcutis 8-K material events explained” filing. Many professionals rely on us for “understanding Arcutis SEC documents with AI” because our platform highlights option-exercise patterns under “Arcutis executive stock transactions Form 4,” flags non-recurring charges, and maps clinical timelines to projected market launches. With comprehensive coverage of every 10-K, 10-Q, 8-K, S-1, and Form 4, plus clear explanations, complex immuno-dermatology disclosures finally make sense.
Todd Franklin Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported planned sales of company common stock under a 10b5-1 trading plan. On 09/08/2025 he sold 9,625 shares at a weighted average price of $17.5376, leaving 891,944 shares reported as directly beneficially owned after that transaction. On 09/09/2025 he sold 504 shares at a weighted average price of $17.5179, leaving 891,440 shares reported as directly beneficially owned after that transaction. The 10b5-1 plan was adopted on June 14, 2024 and has a stated end date of September 30, 2025. The filing also reports indirect holdings: 25,410 shares held by The John Franklin Watanabe Trust, 25,410 shares held by The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares held by Watanabe Ventures, LLC, and 124,956 shares held by The Watanabe 2016 Irrevocable Trust. The Form 4 was signed by an attorney-in-fact on 09/10/2025.
Arcutis Biotherapeutics, Inc. (ARQT) Form 144 reports a proposed sale of 504 common shares by a person for whose account the securities are to be sold, with an aggregate market value of $8,829 and an approximate sale date of 09/09/2025 on NASDAQ. The filing states these 504 shares were acquired on 05/01/2025 upon restricted stock vesting from Arcutis Biotherapeutics.
The filing also discloses prior sales by the same person in the past three months: 11,547 shares on 08/04/2025 for $165,429 and 9,625 shares on 09/08/2025 for $168,800. The filer certifies no undisclosed material adverse information and includes the standard attestation language required by Rule 144.
Masaru Matsuda, SVP General Counsel and Corporate Secretary of Arcutis Biotherapeutics, Inc. (ARQT), reported the sale of 36,130 shares of the issuer's common stock on 09/04/2025. The shares were sold in multiple transactions at prices ranging from $15.93 to $16.3787, with a reported weighted-average sale price of $16.156. Following these dispositions, Mr. Matsuda beneficially owns 161,234 shares. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2025 with a plan end date of September 4, 2026. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
Arcutis Biotherapeutics (ARQT) filed a Form 144 reporting proposed and recent insider sales. The filing names common stock with a proposed sale of 9,625 shares through Merrill (Columbus, OH) with an aggregate market value of $168,800 and an approximate sale date of 09/08/2025 on NASDAQ. The shares were acquired as restricted stock that vested on 05/01/2025, totaling 9,625 shares. The filing also discloses a sale on 08/04/2025 by Todd Franklin Watanabe of 11,547 common shares for gross proceeds of $165,429. The filer certifies no undisclosed material adverse information.
Arcutis Biotherapeutics director Howard G. Welgus executed planned transactions under a 10b5-1 trading plan on 09/02/2025. He exercised a fully vested stock option with a $1.6806 exercise price to acquire 10,000 shares and concurrently sold 10,000 common shares at a weighted average price of $15.6383, with sale prices ranging from $15.45 to $15.81. After these transactions he beneficially owned 100,206 shares. The 10b5-1 plan was adopted March 11, 2025, and runs through May 29, 2026.
Form 144 notice for Arcutis Biotherapeutics, Inc. (ARQT): The filing reports a proposed sale of 36,130 common shares through Merrill (Columbus, OH), with an aggregate market value of $583,716.00, against total outstanding shares of 119,905,078. The approximate date of sale is listed as 09/04/2025 on the NASDAQ. The filing documents the acquisition history for the securities to be sold, showing multiple employer stock purchase plan purchases and restricted stock vesting events between 03/01/2023 and 05/31/2024 totaling the lots listed. The filing also discloses a prior sale by Masaru Matsuda of 6,330 common shares on 08/04/2025 for gross proceeds of $90,687.00. The filer affirms no undisclosed material adverse information.
Insider sale notice for Arcutis Biotherapeutics, Inc. (ARQT). The filer reports a proposed sale of 10,000 common shares via Merrill (Columbus, OH) with an aggregate market value of $156,083 and an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired by stock option exercise on 03/13/2019 and payment is listed as cash. The filing also discloses three sales by Howard Welgus totaling 29,347 shares during June–August 2025, generating gross proceeds of $405,406 combined. The notice includes the standard representation that the seller has no undisclosed material adverse information.
Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold company common stock in two reported transactions under a 10b5-1 plan and to cover tax withholding on vested performance-based restricted stock units. On 08/19/2025 he sold 1,750 shares at a weighted average price of $16.1604, leaving him with 107,249 shares beneficially owned. On 08/21/2025 he sold 2,438 shares at a weighted average price of $15.5738, leaving him with 104,811 shares beneficially owned.
The filing notes the 08/21 trades were effected pursuant to a 10b5-1 trading plan adopted December 12, 2024 (plan end date February 27, 2026). The 08/19 sale was to cover tax withholding on vested performance-based RSUs. Sales occurred in multiple transactions at noted price ranges and the reporting person offers to provide detailed per-trade allocations on request.
Form 144 notice for Arcutis Biotherapeutics, Inc. (ARQT) reports a proposed sale of 2,438 common shares with an aggregate market value of $37,969, against ~119,905,078 shares outstanding. The shares were acquired on 08/18/2025 via restricted stock vesting and the planned sale date is 08/21/2025 through Merrill Lynch on NASDAQ. The filer, identified elsewhere in the form, has completed multiple sales in the prior three months totaling 36,969 shares for gross proceeds of $369,869, indicating ongoing disposition of personal holdings rather than a single large block sale.
Frazier-affiliated investment funds and principals reported holdings in Arcutis Biotherapeutics, Inc. common stock on Schedule 13D/A. Frazier Life Sciences VIII, L.P. directly holds 8,785,284 shares (about 7.3% of the 119,905,078 shares outstanding), and related Frazier entities and principals together report beneficial positions that result in individual aggregates such as 8,843,386 shares for James N. Topper and 8,943,712 shares for Patrick J. Heron (each roughly 7.4–7.5% of the class as reported). The filing states these holdings were acquired for investment purposes, with working capital used as the source of funds for certain purchases. The reporting persons disclose that, except as set forth, they have no present plans to pursue control transactions, board changes, material asset sales, charter amendments, delisting, or similar corporate actions. The Schedule 13D/A updates ownership tables, clarifies sources of funds, and incorporates prior amendments and agreements among the filing entities.
FAQ
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
What is the market cap of Arcutis Biotherapeutics (ARQT)?
